CTOs on the Move

DDB Corbett

www.ddbcorbett.com

 
DDB Corbett is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Apricus Health

Apricus Health is designed by Arizona Physicians to improve access to quality care, while lowering costs.

Isagenix

It is hard to believe that 17 years ago, Jim and Kathy Coover founded Isagenix in partnership with John Anderson and six employees in a small office in Tempe, AZ. Today, we are the largest company by revenue headquartered in Gilbert, AZ, and the 4th largest for-profit company in AZ. We continue to gain recognition and respect for our strong business practices both nationally and internationally. Our honors have included the Better Business Bureau naming us a 2018 BBB Torch Awards for Ethics Finalist in recognition of our commitment to “do the right thing.” In addition, Jim Coover was named 2017 CEO of the Year, and in 2018 and 2019 we were named one of the Best Places to Work, one of the Healthiest Employers, and one of the Valley`s 10 Largest Corporate Philanthropists. Today our family-owned and operated business is in 14 markets, has half a million customers worldwide, and offers more than 100 life-changing products, packs, and systems!

ION Medical

ION Medical is a Mission Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Numoda

Numoda is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoCell MDx

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, we have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of our pipeline. The assay is based on examining specific transcription levels between phagocytic and non-phagocytic cells. This proprietary technology and algorithm has allowed us to not only detect disease but to also, and more importantly, guide the physician as to the grade and aggressiveness of the disease. Our mission is to provide clinicians with quantifiable results that allows professionals to make timely and much more directed medical decisions.